Lakefront Biotherapeutics | GLPG - Operating Expenses


Lakefront Biotherapeutics reported EUR70.18M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
argenx SE USD 1.02B 118M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
Genmab DKK 798M 235M Dec/2025
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
GRIFOLS EUR 1.55B 94M Jun/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Incyte USD 973.64M 4.65B Jun/2026
Merck EUR 4.09B 687M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
UCB EUR 2.96B 196M Dec/2025
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026